---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000068"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:27:17.729574+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant

## Summary
- Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.
- Special meeting of stockholders on March 2, 2023 to approve merger and reverse stock split.
- If compliance not demonstrated by March 10, common stock will be delisted unless further exception granted.
- Company must demonstrate compliance with all initial listing requirements upon closing of merger.

## SEC filing metadata
- accession: 0001485003-23-000068
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/0001485003-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/sesn-20230224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000068
- JSON: https://secwatch.observer/filing/0001485003-23-000068.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.